Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• The Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict.
• Sparc AI approaches that problem from the software side rather than through new hardware, offering its Overwatch platform that delivers precision navigation and target acquisition for drones and autonomous systems.
• The company has also been building the commercial infrastructure to bring that technology to actual defense customers.

Modern militaries-built decades of doctrine on the assumption that satellites would always know where a soldier, drone or missile stood, and that assumption is now breaking down in real time. The Air Force Research Laboratory recently awarded a $49.7 million contract specifically to mature technologies that can operate without GPS, a clear signal that the Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) has spent years building toward this moment, developing software that lets drones and autonomous systems navigate and acquire targets without GPS, radar, lidar or any external signal at all.

The scale of the disruption behind that Air Force contract is difficult to overstate. GPS satellites broadcast extremely weak signals from roughly 20,200 kilometers up, a structural weakness that adversaries have learned to exploit at scale, and IATA’s 2024 safety report documented approximately 430,000 GPS jamming and spoofing incidents over conflict zones that year, up 62% from 2023. A single jamming event tied to Russia’s Kaliningrad exclave disrupted more than 1,600 aircraft over eastern Europe in a two-day span in March 2024, and a cheap software-defined-radio jammer costing roughly $50 can already disrupt GPS across a localized area.

Similar concerns are being reported by Military.com, which noted that autonomous military systems increasingly cannot rely on GPS at all, whether the signal is jammed, spoofed or simply unavailable underground, underwater or beneath dense foliage. ANELLO Photonics CEO Mario Paniccia told the outlet that any autonomous system being built today needs the ability to operate in a GPS-denied or GPS-spoofed environment, and that jamming and spoofing are already happening rather than looming as future risks. These reports point to a defense establishment now actively funding and fielding alternatives rather than debating whether they are needed.

What both reports make clear is that the fix cannot simply be a better GPS. The signal weakness that enables jamming is a matter of physics, not engineering, which is why the Pentagon is funding multiple parallel tracks, from quantum inertial sensors to new low-earth-orbit satellite constellations to fiber optic gyroscopes, each targeting the same underlying problem from a different angle.

SPARC AI approaches that problem from the software side rather than through new hardware. The company’s Overwatch platform was built to deliver precision navigation and target acquisition for drones and autonomous systems. It’s designed to operate in denied, degraded, intermittent and limited environments. Rather than adding new sensors, it converts the low-cost inertial sensors already built into commercial drones into precision instruments through advanced mathematical modeling.  Because the approach is software only, it can be deployed at the price point and scale that modern drone operations require, from a single platform up to fleets numbering in the thousands.

That design also addresses a second battlefield vulnerability beyond GPS dependence: detectability. SPARC AI’s technology is described as zero signature, meaning it does not rely on radar, lidar or other active emissions that can reveal a platform’s position to an adversary. This is an important distinction from many competing navigation approaches that require their own detectable sensors to function. The company has extended that same software architecture into ATLAS, a mission-planning tool launched in October 2025 that runs visibility and line-of-sight simulations entirely in software, eliminating the need for the active sensing hardware that traditional terrain mapping tools require.

SPARC AI has also been building commercial infrastructure to bring that technology to actual defense customers. In November 2025, the company signed a nonexclusive global reseller agreement with Precision Technic Defence Group, a 40-year-old defense integrator with seven offices spanning Europe, the United States and Australia. This agreement gives Sparc AI a distribution channel into established military procurement relationships across those regions. In February 2026, the company announced a separate reseller partnership to bring its platform into Ukraine, beginning with field testing in what the company describes as the world’s most demanding operational environment for GPS-denied drone warfare.

Placed against the backdrop of the Air Force’s $49.7 million alt-navigation contract and the broader shift in Pentagon assumptions, SPARC AI’s positioning appears ideally timed. The company was pursuing GPS-independent navigation and zero-signature target acquisition before this became a funded federal priority, and the recent reports on battlefield GPS failure only reinforce the scale of the market its Overwatch and ATLAS platforms are built to serve.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine
• The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs
• Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers

Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific therapies. By matching treatments to the unique biology of a patient’s tumor, physicians can improve outcomes while reducing unnecessary exposure to therapies that may offer limited clinical benefit (ibn.fm/tNpcJ).

Drug developers are increasingly designing therapies for biomarker-defined patient populations, while regulations, clinicians, and healthcare systems continue to expand the use of genomic testing to guide treatment decisions. As precision oncology becomes the new standard of care, developers capable of creating targeted therapies for genetically defined cancers are positioned to address one of oncology’s fastest-growing markets.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is aligning its development strategy with this industry transformation through ONC010, its lead nanoparticle-encapsulated Polynucleotide kinase-phosphatase (“PNKP”) inhibitor. Designed for biomarker-selected cancers, ONC010 targets tumors that may be particularly susceptible to DNA Damage Response (“DDR”) therapies. The program combines a novel therapeutic target with nanoparticle drug delivery and an AI-native discovery platform, positioning Onco-Innovations within one of oncology’s most promising areas of innovation.

As the company advances toward First-in-Human clinical studies, it is building the scientific and manufacturing foundation supporting ONC010. Recent milestones include the initiation of polymer process development and analytical characterization activities with Nanosoft Polymers, designed to establish a robust, scalable, and reproducible manufacturing platform (ibn.fm/ztsui). According to CEOThomas O’Shaughnessy, “The initiation of this work with Nanosoft represents an important step in strengthening the manufacturing and formulation foundation of ONC010.” He noted that the collaboration is helping establish “a more scalable and reproducible pathway toward future GMP manufacturing and clinical development.”

In parallel, Onco-Innovations has initiated three-species hepatocyte and liver microsome metabolism studies through Nucro-Technics, a key component of its integrated IND-enabling development strategy (ibn.fm/0UaW4). These studies are intended to characterize how ONC010 is metabolized across human, dog, and rat systems, generating data capable of supporting pharmacokinetic modeling, dose selection, toxicology planning, and future regulatory submissions. Together with ongoing chemistry, manufacturing and controls (“CMC”) activities, initiatives are designed to reduce development risk while preparing ONC010 for clinical evaluation.

Onco-Innovations operates at the intersection of precision medicine, targeted oncology, advanced drug delivery, and artificial intelligence. Its integrated development ecosystem combines proprietary PNKP inhibitors, nanoparticle formulation technologies, specialized manufacturing expertise, and AI-driven discovery tools to speed up the development of therapies for biomarker-selected cancers.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

• SS Innovations will showcase its SSi Mantra surgical robotic system at the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting in Florida on July 23-26.
• The presentation will feature a live kidney telesurgery broadcast from India, demonstrating the remote capabilities of the SSi Mantra platform.
• Chairman and CEO Dr. Sudhir Srivastava to participate in multiple conference presentations covering telesurgery, robotic surgery adoption and regulatory developments.
• As of July 6, 2026, more than 12,375 procedures have been completed using the SSi Mantra system, including cardiac, pediatric and telesurgical procedures.
• Approximately 2,100 physicians have already been trained on the platform, which has been used across more than 170 different surgical procedures.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, will bring its SSi Mantra surgical robotic system to one of the largest annual gatherings of robotic surgery specialists, highlighting the company’s expanding clinical experience and growing focus on remote surgical capabilities. The company announced that the SSi Mantra will be showcased during the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting, scheduled for July 23-26 in Hollywood, Florida (https://ibn.fm/FkgsY).

The robotic platform will be demonstrated throughout the conference and featured in multiple technical sessions. One of the event’s focal points will be a live robotic telesurgery in which a partial nephrectomy will be performed remotely by Dr. Amitabh Singh from SS Innovations’ headquarters in Gurugram, India, on a patient at Rajeev Gandhi Cancer Institute and Research Centre in New Delhi.

The planned procedure is intended to demonstrate the capabilities of the company’s telesurgery platform in a live educational setting before surgeons, researchers and medical technology professionals attending the conference.

Company Chairman and Chief Executive Officer Dr. Sudhir Srivastava is also scheduled to participate in several presentations and panel discussions covering cardiac telesurgery, robotic surgery adoption, regulatory considerations, global access to robotic care and developments in soft-tissue robotics.

“This influential forum provides us with a prime opportunity to highlight the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency,” Dr. Srivastava said. “During this year’s event, I will (…) continue to share SS Innovations’ mission of democratizing global access to advanced surgical robotic care.”

SS Innovations has continued expanding the clinical use of its SSi Mantra platform during the past year. According to the company, more than 12,375 multi-specialty procedures had been completed using the robotic system as of July 6, 2026. Those cases include 653 cardiac procedures, 178 telesurgeries, and 225 pediatric surgeries.

The company also reports that approximately 2,100 physicians have received training on the SSi Mantra platform, which has been used in more than 170 different surgical procedures across multiple specialties. Those figures reflect continued growth in clinical utilization, an important metric for companies developing surgical robotics because expanding physician adoption typically generates additional experience, procedural data and training opportunities.

The SSi Mantra is designed as a modular robotic surgery platform capable of supporting a broad range of minimally invasive procedures. Its architecture includes three to five robotic arms, an open-console surgeon workstation, three-dimensional 4K visualization, integrated imaging capabilities and a suite of more than 40 robotic surgical instruments supporting specialties that include general surgery, urology, gynecology, cardiac surgery, pediatric surgery and ear, nose and throat procedures.

Among the platform’s distinguishing features is the optional SSi MantrAsana tele-surgeon console, which enables surgeons to perform procedures remotely while maintaining functionality comparable to the standard operating console.

Remote surgery remains an emerging segment within robotic medicine. While regulatory, technical and infrastructure challenges continue to shape its adoption, proponents believe telesurgery could eventually expand access to specialized surgical expertise for patients in underserved regions.

SS Innovations has stated that the SSi Mantra is the only surgical robotic platform to have been used for cardiac telesurgery. Although telesurgery continues to evolve and currently represents a relatively small portion of overall robotic surgery activity, the company views the capability as an important component of its long-term technology strategy.

Beyond remote surgery, SS Innovations continues to position the SSi Mantra as a cost-conscious alternative within the broader robotic surgery market. The company says its objective is to make robotic-assisted procedures more affordable and accessible while supporting hospitals that may face financial barriers to adopting existing robotic systems. That strategy combines technology development with physician training, clinical validation and international expansion.

SS Innovations has steadily increased both the number of installed systems and the range of procedures supported by its platform. Earlier this year, the company announced that the SSi Mantra had surpassed 10,500 cumulative procedures, a figure that has continued to grow as adoption expands.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• Canamera has commenced exploration at its São Sepé Project in Brazil, where three high-priority rare earth targets have already been identified
• The company is building a diversified Brazilian rare earth portfolio as Western nations seek alternatives to China’s supply dominance
• These developments position Canamera to capitalize on growing demand for secure, strategic sources of critical minerals

Rare earth elements have become indispensable to the technologies powering the global economy, from electric vehicles and wind turbines to advanced defense systems and consumer electronics. Yet despite their strategic importance, global supply chains remain heavily concentrated, with China accounting for more than 60% of rare earth mining and roughly 90% of processing capacity. As geopolitical tensions and export restrictions reshape global trade, governments and manufacturers are increasingly seeking reliable alternative sources of these critical materials (ibn.fm/7Shls).

Brazil is emerging as one of the most promising alternatives.

With favorable geology, well-established mining expertise, supportive government policies, and growing exploration activity, Brazil has become an increasingly attractive destination for companies developing rare earth resources outside China’s sphere of influence. Among those positioning themselves to benefit from this trend is Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF), a critical minerals exploration company advancing a growing portfolio of rare earth projects in Brazil and across the Americas (ibn.fm/vtoAW).

The company’s latest milestone came with the commencement of exploration at its São Sepé Rare Earth Project in Rio Grande do Sul. Historical exploration identified three high-priority target areas (Erica, Sara and Maya) where soil sampling returned encouraging Total Rare Earth Oxide (“TREO”) values along with anomalous concentrations of the valuable heavy rare earth elements dysprosium and terbium.

Dysprosium and terbium play a critical role in manufacturing high-performance permanent magnets used in electric vehicles, offshore wind turbines, robotics, aerospace systems and advanced defense technologies.

To advance the project, Canamera recently launched an approximately 500-meter auger-drilling program designed to evaluate the grade and lateral continuity of potential ionic adsorption clay-hosted mineralization. Ionic clay deposits have attracted significant industry attention because they can often offer lower-cost extraction methods compared to conventional hard rock rare earth deposits while yielding many of the high-value heavy rare earth elements essential to next-generation technologies.

Importantly, the geological setting at São Sepé shares notable similarities with Brazil’s Serra Verde deposit, one of the world’s most significant ionic clay rare earth discoveries outside China. Combined with excellent road infrastructure and favorable logistics, the project offers several characteristics that could support efficient exploration and future development.

São Sepé complements Canamera’s broader Brazilian exploration strategy, alongside its Turvolândia Project, as the company continues assembling a portfolio of district-scale rare earth opportunities in jurisdictions increasingly viewed as strategically important to Western supply chains.

As governments and manufacturers work to diversify critical mineral sourcing amid rising geopolitical uncertainty, companies with exposure to emerging rare earth districts may become increasingly relevant. By advancing multiple Brazilian rare earth assets while targeting the rapidly emerging ionic clay segment, Canamera is positioning itself to benefit from one of the most significant long-term trends in the critical minerals sector. As governments and manufacturers continue seeking secure, diversified supply chains, the company’s growing Brazilian portfolio could become increasingly relevant to the global rare earth market.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program.
• The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform.
• VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies.
• The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting.
• VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered antibody formats.
• The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).

Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability and study design.

According to VERAXA, discussions with the PEI focused on the biological mechanism underlying its dual-targeting BiTAC(R)-TCE platform together with its proposed pharmacokinetic strategy and planned non-clinical safety assessments. The company said the feedback indicated that regulators understood the scientific rationale supporting the technology and the proposed development approach. VERAXA believes this provides greater clarity regarding the path forward while reducing some of the uncertainty typically associated with advancing a novel therapeutic modality.

“Scientific Advice on the first therapeutic candidate based on a novel platform is an important early validation, and the feedback we received is encouraging,” said Christoph Erkel, Ph.D., Vice President, Research & Development of VERAXA. “It indicates that the regulatory authorities understand the biological rationale behind our BiTAC-TCE technology approach and gives us greater clarity on the development path we have proposed. For our new modality, such early alignment is crucial to make sure that we progress as efficiently as possible towards the clinics.”

VERAXA’s lead program is built around its proprietary BiTAC(R)-TCE technology, a conditionally active bispecific T-cell engager designed to recognize two target molecules before activating an immune response against cancer cells.

Traditional T-cell engagers have shown promise in oncology but may also activate immune cells against healthy tissues expressing similar targets. VERAXA’s dual-targeting approach is intended to improve selectivity by attacking cancer cells displaying both target markers while reducing activity against cells expressing only one.

The company’s most advanced BiTAC(R)-TCE candidate generated preclinical data presented during the American Association for Cancer Research (“AACR”) Annual Meeting 2026 in April. According to VERAXA, laboratory and animal studies showed the candidate behaved as intended by selectively targeting cancer cells carrying both biomarkers while sparing cells with only a single target. The company also reported that the program demonstrated efficacy comparable to a more conventional T-cell engager while producing a safety profile that could support an improved therapeutic index if confirmed in future studies.

The latest announcement also reflects continued execution of VERAXA’s broader development strategy. The company is building a diversified oncology pipeline centered on next-generation antibody therapeutics. In addition to its BiTAC(R) platform, VERAXA is developing bispecific antibody-drug conjugates (“ADCs”), additional mono- and bispecific ADC candidates, and other engineered antibody formats designed to address multiple forms of cancer.

The company traces its scientific origins to discoveries made at the European Molecular Biology Laboratory (“EMBL”), where research into antibody engineering helped establish the foundation for its current technology platforms. VERAXA has continued advancing several elements of its development program in recent months. Earlier this month, the company announced progress in cell-line development for its lead BiTAC(R)-TCE candidate, an important manufacturing step intended to support future investigational studies and eventual clinical-scale production.

Cancer immunotherapy remains one of the most active areas of drug development, with researchers seeking therapies capable of improving efficacy while reducing treatment-related toxicity. Bispecific antibodies and T-cell engagers have become an increasingly important area of research because they recruit immune cells directly to cancer cells, potentially improving treatment precision.

VERAXA’s BiTAC(R) approach seeks to build on that concept by introducing conditional activation designed to increase tumor selectivity. The company’s immediate focus remains on completing non-clinical development, validating manufacturing capabilities and preparing regulatory submissions required before clinical testing can begin.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies.
• Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
• The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover.

Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.

Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the work; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. The prevalence of the disease is also increasing.

The disease attacks the myelin sheath, the protective coating surrounding nerve fibers in the brain and spinal cord. When myelin is damaged, communication between the brain and body breaks down. The result can be numbness, vision problems, mobility impairment, cognitive difficulties and, over time, serious and lasting disability.

Available treatments can slow the progression of the disease and can even reduce relapses, but no existing options have been shown to reliably halt or reverse the underlying nerve damage. Companies are working to change that: The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is projected to reach $38.6 billion by 2030, a reflection of how large and persistent the unmet clinical need remains.

Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Rather than modulating the immune system, Lucid-MS targets protein arginine deiminase 2 (“PAD2”), an enzyme directly involved in myelin degradation. The goal is to protect and potentially restore the myelin sheath itself, addressing the underlying cause of disability rather than managing symptoms.

In preclinical animal models, Lucid-MS accelerated functional recovery, preserved myelin and reduced damage in MS mouse models. Phase 1 clinical trials in healthy human volunteers confirmed a favorable safety profile, with the drug well tolerated and no significant safety concerns reported. In March 2026, the company submitted an Investigational New Drug application to the U.S. FDA for a phase 2 trial.

In April 2026, the company announced that it had formally submitted an Investigational New Drug application to the U.S. FDA for a phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.

Supporting the phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The study uses a novel PET imaging tracer, [¹⁸F]3F4AP], developed by researchers at MGH and Harvard Medical School. The tracer is designed to directly visualize demyelinated neurons with intact axons, offering a more precise way to measure myelin damage and repair than any currently available technique. Enrollment in the pilot study recently reached its halfway point, with early imaging data showing a robust signal in acute MS lesions.

Alcohol’s impact on the brain is Quantum BioPharma’s second area of focus. Alcohol is one of the most widely consumed and heavily studied psychoactive substances on the planet, responsible for an estimated 2.6 million deaths annually. Alcohol use impairs cognition, slows reaction times, disrupts physiological function and contributes to an enormous global burden of harm. The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour. Quantum BioPharma challenged that assumption.

The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour, as the liver processes alcohol at a largely fixed rate. Quantum BioPharma challenged that assumption.

The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. In a double-blind, randomized, placebo-controlled clinical trial, unbuzzd reduced blood alcohol concentration more than 40% faster than placebo within the first 30 minutes after consumption. Participants also reported statistically significant improvements in alertness, reduced headache severity and fewer symptoms of impairment. No adverse side effects were reported.

Those results were published in the “World Journal of Pharmaceutical and Medical Research” earlier this year. The publication marked a meaningful scientific validation for a product, available online, that now sits at the intersection of consumer wellness and clinical evidence. 

Together, Lucid-MS and unbuzzd reflect a company committed to applying rigorous science where existing solutions have fallen short. Quantum BioPharma is advancing both assets with clinical data, peer-reviewed evidence and regulatory engagement, bringing genuine scientific innovation to two areas where patients have long needed better answers. 

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• The company has received a Texas DSHS Certificate of Registration for Industrial Radiation Machines, allowing research and development activities involving its registered Texatron(TM) Fusion Engine(TM) systems at Texas Tech University.
• The registration provides the principal regulatory authorization supporting the company’s planned engineering, prototype testing, and validation roadmap, under applicable Texas radiation control regulations.
• The certificate covers 12 Texatron(TM) Fusion Engine(TM) research systems, ranging from 500 kW to 1 GW, reflecting the breadth of the company’s planned development platform.
• The milestone follows months of regulatory review and supports the next phase of the company’s technical development program, including calibration, diagnostics and prototype validation.
• American Fusion(TM) Chief Technology Officer Dr. John Brandenburg is scheduled to introduce the Texatron(TM) Fusion Engine(TM) platform at a scientific conference at Fermilab on July 23, providing an opportunity for engagement with researchers and engineers.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has reached another step in its development program after receiving a Certificate of Registration for Industrial Radiation Machines from the Texas Department of State, Health Services, providing regulatory authorization to conduct testing, research and development involving its Texatron(TM) Fusion Engine(TM) systems at Texas Tech University in Lubbock, Texas.

The announcement, released on July 17, marks the completion of a regulatory review process that began several months earlier and establishes the framework under which the company can proceed with planned engineering, prototype testing and technical validation activities (https://ibn.fm/E1ZNj).

According to American Fusion(TM), the registration authorizes the company to receive, possess, acquire, transfer and use registered industrial radiation machines for research purposes in accordance with the Texas Radiation Control Act, applicable state regulations and the company’s radiation safety program.

The registration remains effective through February 28, 2034, and identifies Chief Technology Officer Dr. John E. Brandenburg as Radiation Safety Officer. The company noted that no other known material permits, licenses or regulatory approvals are required to conduct its planned testing program for the 500KW and 5 MW Texatron(TM) Fusion Engines(TM) at its approved Texas Tech research location.

American Fusion(TM) says the registration provides the regulatory structure supporting testing, research, prototype development, calibration, diagnostic evaluation and engineering validation rather than commercial deployment.

The certificate also covers a broad family of Texatron(TM) Fusion Engine(TM) research systems, authorizing work on twelve configurations ranging from 500 kilowatts to one gigawatt. Those systems include 500 kW, 1 MW, 5 MW, 10 MW, 20 MW, 30 MW, 50 MW, 75 MW, 100 MW, 250 MW, 500 MW and 1 GW research platforms.

Executive Chairman Brent Nelson described the approval as the result of years of engineering preparation, radiation safety planning and regulatory coordination, while Chief Legal Officer Michael G. Smith said the process reflected collaboration across engineering, legal, technical and regulatory teams.

Independent Director Fabrice David added that the company continues to focus on engineering innovation alongside regulatory compliance and scientific discipline as development progresses. “Today’s announcement reflects another important step in the company’s continued development. The combination of engineering innovation, regulatory discipline, and scientific rigor continues to position American Fusion for the next phase of its research and development program,” David said.

The registration supports American Fusion’s(TM) stated strategy of advancing the Texatron(TM) Fusion Engine(TM) through staged engineering work rather than attempting to accelerate directly toward commercialization. Planned activities include equipment calibration, diagnostic measurements, prototype refinement and technical validation under controlled testing conditions. 

That incremental approach also aligns with another event on the company’s calendar. On July 23, Dr. Brandenburg is scheduled to introduce the Texatron(TM) Fusion Engine(TM) platform during a scientific conference at Fermi National Accelerator Laboratory (“Fermilab”) in Batavia, Illinois (https://ibn.fm/34EI7).

According to the company, the presentation will introduce conference participants to its compact pulsed-fusion development platform, underlying confinement concepts, expanding patent portfolio and planned testing activities.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide.
• Study is evaluating technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent.
• Quantum BioPharma reports two key developments: patient enrollment in the pilot study has reached its halfway mark and preliminary imaging data is encouraging.

A key imaging study examining a novel approach to tracking multiple sclerosis (“MS”) has reached its halfway point in patient enrollment, with early results showing a meaningful signal in MS lesions. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, announced the milestone as part of its ongoing imaging collaboration with Massachusetts General Hospital, where researchers are evaluating a novel positron emission tomography (“PET”) imaging tracer that could support the development of Lucid-MS, the company’s MS drug candidate.

Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person’s life.

The disease attacks the central nervous system by damaging myelin, the protective coating around nerve fibers. This damage disrupts communication between the brain and the rest of the body. Symptoms can range from fatigue, numbness and vision problems to severe mobility impairment, cognitive difficulty and paralysis. The course of MS is unpredictable, and for many patients, the disease progresses in ways that are difficult to foresee or control.

Treatments exist that can slow the disease’s progression and reduce the frequency of relapses. But no therapy has yet demonstrated the ability to reliably halt or reverse the underlying nerve damage that drives long-term disability. That gap represents one of the central unmet needs in modern neurology. Better ways of measuring that damage, and of knowing whether a drug is actually protecting or repairing the nervous system, are urgently needed.

This is where Quantum BioPharma’s work with Massachusetts General Hospital becomes particularly significant. The study centers on a novel PET imaging technique using the tracer [¹⁸F]3F4AP, developed by Dr. Pedro Brugarolas, an investigator in radiology at MGH and assistant professor at Harvard Medical School. The technique is designed to detect demyelinated neurons that still have intact axons. That distinction matters enormously. It allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent.

The announcement highlights two key developments. First, patient enrollment in the pilot study has reached its halfway mark. Reaching that midpoint is a meaningful operational signal. It indicates the study is progressing on schedule and moving toward the dataset size needed to draw reliable conclusions.

Second, the preliminary imaging data is encouraging. The first cohort of participants has been imaged using both advanced PET/MR and total-body PET platforms. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. If those early findings hold as enrollment continues, the imaging approach could provide a more direct and quantitative way to track myelin loss and repair over time.

“We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data,” said Quantum BioPharma VP over scientific and clinical affairs Dr. Andrzej Chruscinski. “PET imaging with [¹⁸F]3F4AP has the potential to fundamentally change how we assess demyelination, providing a direct window into axonal health and enabling us to more clearly demonstrate the impact of therapies like Lucid-MS that aim to protect and restore the myelin sheath in MS.”

Brugarolas added that the ability to directly quantify demyelinated lesions with intact axons in living patients fills an important gap in MS research. “If further validated, this imaging approach could provide a more direct and quantitative measure of myelin loss and repair, which may help improve the evaluation of disease mechanisms and therapeutic response in MS,” he said.

These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. Lucid-MS previously completed phase 1 clinical trials with a favorable safety profile and was well tolerated in healthy participants, providing a strong foundation for the next stage of development. In March 2026, the company submitted an Investigational New Drug application to the FDA for a phase 2 trial.

A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• BOXABL is advancing a factory-based approach to housing that seeks to standardize production and improve cost efficiency in a traditionally fragmented industry.
• The company is targeting a large addressable market supported by a significant housing supply gap and long-term affordability challenges.
• Its modular system is designed to scale across multiple use cases, from individual homes to large residential and commercial developments.
• The company is embedding automation and AI into factory operations to improve throughput, reduce defects, and optimize production efficiency.
• BOXABL’s model pairs lower-margin home production with higher-margin service opportunities such as financing, insurance, and maintenance.

BOXABL (NASDAQ: BXBL) is a technology company focused on transforming residential construction through a factory-built, modular housing system designed for scale. By shifting homebuilding from traditional on-site processes to controlled manufacturing environments, the company aims to introduce a more standardized, efficient and repeatable approach to housing production. Its model integrates design, engineering and manufacturing into a unified system intended to improve speed, cost predictability and overall accessibility.

The company’s approach is rooted in addressing persistent structural challenges across the housing market, including affordability constraints, regulatory complexity and declining construction productivity. BOXABL’s platform is designed to streamline the building process by reducing reliance on fragmented workflows and enabling consistent output through automation and standardized components. This system-level strategy is intended to support a wide range of housing applications while improving efficiency across the value chain.

The company is headquartered in Las Vegas, Nevada.

Products

BOXABL’s product platform is built around a modular housing system designed for factory production, transportation efficiency and on-site deployment. Its core innovation is a folding building structure that allows homes to ship compactly on standard trailers and then unfold on-site into full residential units. This approach is intended to convert homebuilding into a repeatable manufacturing process with consistent quality and predictable costs.

The company’s flagship product line is the Casita, a fully finished modular home offered in multiple configurations, including studio, one-bedroom and two-bedroom layouts. Each unit includes a full kitchen, bathroom, and living space and can be delivered as a turnkey solution with financing and installation depending on the program. BOXABL also offers the Baby Box, a smaller unit built to RV code and designed for simpler setups without traditional foundation requirements, expanding accessibility and deployment flexibility.

The same modular system is designed to scale beyond individual units into larger residential and commercial applications, including single-family homes, townhomes, multifamily housing, hotels and mixed-use developments. BOXABL supports these applications through a 400,000-square-foot factory complex in Las Vegas, where it has produced more than 800 homes to date, and through a diversified go-to-market strategy that includes homeowners, builders, developers, commercial partners, and public sector deployments.

Market Opportunity

BOXABL is targeting a large and structurally undersupplied housing market, which the company estimates at approximately $2.2 trillion in total addressable demand. This figure is based on an estimated need for more than 5.4 million homes, including a 4.03 million unit shortfall combined with approximately 1.36 million annual housing starts at a median price point of around $405,000.

Within this broader market, the company focuses on the modular and manufactured housing segment, representing a serviceable addressable market of approximately $36 billion, based on roughly 103,000 manufactured homes shipped in 2024. BOXABL estimates its initial serviceable obtainable market at approximately $1 billion, based on a single-factory production capacity of 5,000 homes per year and an average turnkey price of approximately $175,000 per unit.

The company also highlights several structural drivers supporting demand, including affordability challenges affecting approximately 75% of U.S. households, a housing shortfall estimated at 4.7 million units, and regulatory burdens that can increase construction costs by roughly 42%. Additionally, construction productivity has declined significantly since 1970, reinforcing the potential need for alternative approaches that emphasize standardization and factory-based production.

Leadership Team

Paolo Tiramani, Co-Founder and Co-Chief Executive Officer, is an American entrepreneur with backgrounds in industrial design and mechanical engineering and has been associated with more than 150 patent filings, including work involving intellectual property licensing to Fortune 500 companies.

Galiano Tiramani, Co-Founder and Co-Chief Executive Officer, is a serial entrepreneur with experience in cryptocurrency arbitrage, Bitcoin ATM operations and agricultural ventures, contributing to the company’s focus on unconventional business models and emerging opportunities.

Kyle Denman, Co-Founder and Chief Product Officer, holds a Bachelor of Science in Mechanical Engineering and has contributed to numerous civil and automotive mechanical patent filings, supporting the development of BOXABL’s modular engineering platform.

Martin Costas, Chief Financial Officer, has held senior finance roles across organizations including Honeywell, Schlumberger, Nexans, Sysco and PwC, bringing experience in financial operations, reporting and corporate scale.

Shan Palaniappan, Chief Technology Officer, has more than two decades of experience in enterprise software and platform engineering, with prior leadership roles at Sagent, DataRobot and Salesforce, where he focused on cloud infrastructure and AI-enabled systems.

For more information, visit the company’s website at www.BOXABL.com/ir.

NOTE TO INVESTORS: The latest news and updates relating to BXBL are available in the company’s newsroom at https://ibn.fm/BXBL

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• The demand for key elements, including neodymium and praseodymium, and metals such as niobium, is only increasing.
• Canamera’s recent report recommends a diamond drill program of 1,500 meters across nine holes at its Schryburt Lake project.
• CEO states that “Schryburt Lake is a rare and genuinely underexplored carbonatite system in one of Canada’s most active mining districts.”

The magnets that spin electric vehicle motors and offshore wind turbines cannot be built without a small basket of rare earth elements led by neodymium and praseodymium. In addition, the high-strength steel alloys that reinforce pipelines, jet engines and defense infrastructure depend just as heavily on niobium, a metal whose supply is even more geographically concentrated than the rare earths. In that context, Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF), one of the junior exploration companies working to build supply of these essential elements, has filed an independent NI 43-101 technical report on its Schryburt Lake project in northwestern Ontario, recommending a C$1.5 million phase 1 drill program targeting rare earth and niobium mineralization across five priority target areas.

Neodymium and praseodymium, often referred to together as NdPr, are the specific rare earth elements used to make the high-performance permanent magnets found in electric vehicle motors, wind turbine generators, robotics and defense systems. In addition, the announcement of a recent supply agreement underscores just how central non-China NdPr sourcing has become to magnet manufacturers. 

That urgency is not abstract. A May 2026 analysis from the Center for Strategic and International Studies describes how, a year after Beijing tightened rare earth export controls, the United States has been racing to build alternative supply relationships with Australia, Japan and other partners, precisely because China still dominates global rare earth processing capacity.

Niobium plays a comparably outsized role, but its supply is concentrated even more tightly, in a single country. A recent analysis of niobium’s geopolitics notes that Brazil holds a near-monopoly on global production and reserves. The report also observed that there are no direct substitutes equivalent to niobium in its most critical applications, particularly microalloyed steels and high-performance superalloys used in aerospace, turbines and pipelines. One market overview puts Brazil’s share of global niobium production at roughly 90%, adding that Canada is the only other significant source, which is precisely the jurisdiction where Canamera’s Schryburt Lake project is located.

Canamera’s technical report, effective April 15, 2026, was authored by J Garry Clark, P.Geo. of Clark Exploration Consulting Inc., an independent qualified person. This report is the first comprehensive third-party technical assessment of Schryburt Lake since Canamera optioned the project. The report recommends a diamond drill program of 1,500 meters across nine holes. 

The budget outlined in the report is C$1,403,575, which includes a 15% contingency. Drilling will use helicopter-supported BQTW core rigs. One additional hole may be added depending on real-time portable X-ray fluorescence screening of core from the initial holes. The program targets five priority areas across the Schryburt Lake Carbonatite Complex. Four are established targets: Blue Jay, Goldfinch, Starling and Blackbird. The fifth, Hummingbird, is a newly added target exploration target that may be evaluated during phase 1.

These targets are grounded in real sample data, not just speculation. In 2023, a rock chip sample from the Blue Jay target returned 3.59% total rare earth oxides and 0.47% niobium pentoxide. Some individual samples graded as high as 0.66% niobium pentoxide.

A 3D magnetic inversion model, also completed in 2023, identified multiple pipe-like magnetic anomalies beneath several of the targets. These anomalies extend to depths of 600 to more than 1,000 meters, suggesting meaningful vertical exploration potential.

The project sits roughly 135 kilometers north-northeast of Pickle Lake, in Ontario’s Patricia Mining Division, an active mining region. Canamera holds the right to earn up to a 90% interest in the project under its joint venture option agreement with Bindi Metals Limited.

Canamera has applied for the Ontario Exploration Permit required to begin drilling and is continuing engagement with the Kingfisher Lake, Mishkeegogamang, Nibinamik and Wunnumin Lake First Nations as it advances toward field work. “Schryburt Lake is a rare and genuinely underexplored carbonatite system in one of Canada’s most active mining districts,” said Canamera CEO Brad Brodeur. “We believe it offers our shareholders the potential of differentiated exposure to permanent-magnet rare earths and niobium at a time of intense strategic focus on Western critical mineral supply chains.”

The Schryburt Lake report lands amid a run of exploration progress across Canamera’s broader portfolio. Just days earlier, the company expanded its auger drill program at the Turvolândia rare earth project in Brazil by 20%, after a drill hole there returned 3,255 parts per million total rare earth oxides over 13 meters from surface. The company also completed an 11-hole drill program at its Brazil-based Patos project, where field geology pointed to a distinct kamafugite-hosted rare earth target profile. 

Taking together, these updates mark significant progress for Canamera. The Schryburt Lake technical report gives the company a Canadian rare earth and niobium project with an independently reviewed development pathway. This adds to a portfolio that already includes ionic clay rare earth exploration in Brazil and critical mineral assets in the United States.

Canamera now has multiple, geologically distinct paths toward Western-sourced rare earth and niobium supply. That supply appears to offer exactly what magnet manufacturers and steelmakers are increasingly seeking.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.